Global Bevacizumab Biosimilars Market Analysis by Capital Investment, Industry Outlook, Growth Potential, Opportunities and Trends – Shanghaiist

0

Bevacizumab is a recombinant humanized monoclonal antibody that prevents vascular endothelial growth factor-A (VEGF-A) from having its physiological effect (an essential endothelial cell mitogen and survival factor). It is the first anti-angiogenic drug to be given the green light for use in the treatment of human cancer. The drug was created by F. Hoffmann-La Roche AG and received US Food and Drug Administration (FDA) approval in February 2004 as a first-line therapy for the treatment of metastatic colorectal cancer when is associated with intravenous chemotherapy based on 5-fluorouracil. In the United States and Europe, bevacizumab has been approved for use in the treatment of patients with cancer of the cervix, epithelial ovary, or fallopian tubes. Bevacizumab is also licensed for the treatment of people with non-small cell lung cancer or renal cell carcinoma that has spread. Additionally, it is approved for use in the treatment of glioblastoma patients in the United States, and it is approved for use in the treatment of metastatic breast cancer in Europe. Bevacizumab received the green light from the European Medicines Agency in 2005 and is now sold under the brand name Avastin.

Request for sample pages:

https://www.insightaceanalytic.com/request-sample/1073

Hetero
Amgen
Biocon
Mylan Inc.
Therapeutic BioXpress
Celltrion
Teva Pharmaceutical Industries
Pfizer
Samsung Bioepis
mAbxience
and among others.

Global Bevacizumab Biosimilars Market SegmentationGlobal Bevacizumab Biosimilars Market Outlook (Revenue, USD Million, 2019-2030) by Product
Avastin
Mvasi
Zirabev
Aybintio
Other clinical trial products

Global Bevacizumab Biosimilar Market Outlook (Revenue, USD Million, 2019 – 2030) by Application
Colorectal cancer
Non-small cell lung cancer
Glioblastoma
Renal cell carcinoma
Cervical cancer
Ovarian cancer

Global Bevacizumab Biosimilar Market Outlook (Revenue, USD Million, 2019 – 2030) by Distribution Channel
Hospital pharmacy
Online pharmacy
Retail pharmacy
Other direct distribution channels

For more information :

https://www.insightaceanalytic.com/report/global-bevacizumab-biosimilar-market/1073

About Us:

InsightAce Analytic is a market research and consulting company that empowers clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market intelligence and competition to grow businesses. We help our clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in delivering syndicated and customized market intelligence reports with in-depth analysis with key market insights in a timely and cost effective manner.

Contact us:

InsightAce Analytics Pvt. ltd.

Such. : +1 551 226 6109

Email: [email protected]

Site visit: www.insightaceanalytic.com

Follow us on LinkedIn @ bit.ly/2tBXsgS

Follow us on Facebook @ bit.ly/2H9jnDZ

Share.

Comments are closed.